Clinical Trial Search

Primary: Total Number of Adverse Events — 7; 7; 3; 7 Number of Adverse Events

Primary: Total Number of Adverse Events — 9; 15; 5; 12 Total Number of AE

Primary: Study Related Serious Adverse Events (SR-SAE) — 0 Events

Primary: Cmax - the Maximum Plasma Concentration — 18048; 16007; 17042 ng/mL

Primary: Cmax - Maximum Observed Plasma Drug Concentration — 22210; 16667; 12195; 685 ng/mL

Primary: Cmax - Maximum Steady-state Plasma Concentration — 27571; 2,350; 1,909 ng/mL

Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL

Primary: Cmax - Peak Plasma Concentration — 14286.790; 18677.265; 15055.632; 14974.79 ng/mL

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 8; 2; 2; 1 participants

Primary: Determine Dose Limiting Toxicities (DLTs) of VELCADE When Administered in Combination With IFN-α-2b to Patients With Metastatic Malignant Melanoma. — 3; 1 toxicities

Primary: Number of Adverse Events Reported — 10; 7; 7 Number of adverse events reported

Primary: Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration…

Primary: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization — 6.96; 8.33 units on a scale — p=0.1815

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) for Simvastatin — 38.142; 26.601 ng*h/ml

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Midazolam — 103.348; 120.1 ng*hr/mL